Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study

Vaccine

Volumn 36, Issue 28, 2018, Pages 4112-4117

  de Menezes Martins, Reinaldo ^a   Maia, Maria de Lourdes S ^a   de Lima, Sheila Maria Barbosa ^a   de Noronha, Tatiana Guimarães ^a   Xavier, Janaina Reis ^a   Camacho, Luiz Antonio Bastos ^b   de Albuquerque, Elizabeth Maciel ^a   Farias, Roberto Henrique Guedes ^c   da Matta de Castro, Thalita ^a   Homma, Akira ^a  

^a Instituto de Technologia em Imunobiologicos   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Brazilian Army Health Service   (Brazil)

Author keywords

Dose response study; Duration of immunity; Fractionated vaccine; Immunogenicity; Yellow fever vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EPIDEMIC; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTECTION; SEROCONVERSION; VACCINE IMMUNOGENICITY; YELLOW FEVER; COHORT ANALYSIS; DOSE RESPONSE; IMMUNOLOGY; SOLDIER; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; VOLUNTEER;

COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MILITARY PERSONNEL; TIME FACTORS; VOLUNTEERS; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 85047221929     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2018.05.041     Document Type: Article

References (16)

1. Shearer, F.M., Moyes, C.L., Pigott, D.M., Brady, O.J., Marinho, F., Deshpande, A., et al. Lancet Infect Dis 17:11 (2017 Nov), 1209–1217, 10.1016/S1473-3099(17)30419-X Epub 2017 Aug 16.
2. Wilder-Smith, A., Yellow fever vaccination: estimating coverage. Lancet Infect Dis 17:11 (2017 Nov), 1109–1111.
3. Monath, T.P., Woodall, J.P., Gubler, D.J., Yuill, T.M., Mackenzie, J.S., Martins, R.M., et al. Yellow fever vaccine supply: a possible solution. The Lancet 387:10028 (2016 Apr), 1599–1600.
4. WHO. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. WHO Secretariat information paper. WHO; 20 July 2016.
5. http://www.who.int/immunization/sage/meetings/2016/october/Session11-Part2-Feedback-from-the-yellow-fever-mass-vaccination-campaign-using-fractional-dose.pdf.
6. http://www.who.int/immunization/sage/meetings/2016/october/Session11-Part2-Fractional-dosing-of-Yellow-fever-vaccines.pdf?ua=1.
7. Yellow fever vaccine: WHO position on the use of fractional doses – June 2017. Wkly Epidemiol Rec. 2017 23;92(25):345–50.
8. de S Lopes, O., Guimarães, S.S., de Carvalho, R., Studies on yellow fever vaccine. III–Dose response in volunteers. J Biol Stand 16:2 (1988 Apr), 77–82.
9. Martins, R.M., Maia de, M.L.S., Farias, R.H.G., Camacho, L.A.B., Freire, M.S., Galler, R., et al. 17DD yellow fever vaccine: a double-blind, randomized clinical trial of immunogenicity and safety in a dose-response study. Human Vaccines Immunother 9:4 (2013 Apr), 879–888.
10. Campi-Azevedo AC, de Almeida Estevam P, Coelho-dos-Reis JG, Peruhype-Magalhães V, Villela-Rezende G, Quaresma PF, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Inf Dis [Internet]. 2014 Dec [cited 2018 Jan 30];14(1). Available from: < http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-391>.
11. Gotuzzo, E., Yactayo, S., Cordova, E., Review article: efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 89 (2013), 434–444.
12. Ahuka-Mundeke, S., Casey, R.M., Harris, J.B., Dixon, M.G., Nsele, P.M., Kizito, G.M., et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak – preliminary report. N Engl J Med, 14, 2018 Feb.
13. Campi-Azevedo, A.C., Costa-Pereira, C., Antonelli, L.R., Fonseca, C.T., Teixeira-Carvalho, A., Villela-Rezende, G., et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Human Vaccines Immunotherapeutics 12:2 (2016 Feb), 491–502.
14. Collaborative group for studies on yellow fever vaccines, Duration of post-vaccination immunity against yellow fever in adults. Vaccine 32 (2014), 4977–4984.
15. SAGE Working Group. Background paper on yellow fever vaccine. Version: 2013, March, 19th. Obtained at < http://www.who.int/immunization/sage/meetings/2013/april/1_Background_PaperYellow_Fever_Vaccines.pdf> [2018/02/04], at 3:19 PM.
16. WHO. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. Replacement of the annex 2 of WHO Technical Report series, N° 872 and of the amendment to the annex in WHO Technical Report series, N° 2012;944.